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ABSTRACT 
 The translocator protein (TSPO) is a commonly used imaging target to 
investigate neuroinflammation. While TSPO imaging demonstrates great promise, its 
signal exhibits substantial interindividual variability, which needs to be accounted for to 
uncover group effects that are truly reflective of neuroimmune activation. Recent 
evidence suggests that relative metrics computed using pseudo-reference approaches 
can minimize within-group variability, and increase sensitivity to detect physiologically 
meaningful group differences. Here, we evaluated various ratio approaches for TSPO 
imaging and compared them with standard kinetic modeling techniques, analyzing two 
different disease cohorts.  
Patients with chronic low back pain (cLBP) or amyotrophic lateral sclerosis (ALS) 
and matching healthy controls received 11C-PBR28 PET scans. Occipital cortex, 
cerebellum and whole brain were first evaluated as candidate pseudo-reference regions 
by testing for the absence of group differences in Standardized Uptake Value (SUV) and 
distribution volume (VT) estimated with an arterial input function (AIF). SUV from target 
regions (cLBP study – thalamus; ALS study – precentral gyrus) was normalized with SUV 
from candidate pseudo-reference regions to obtain SUVRoccip, SUVRcereb, and SUVRWB. 
The sensitivity to detect group differences in target regions was compared using various 
SUVR approaches, as well as distribution volume ratio (DVR) estimated with (blDVR) or 
without AIF (refDVR), and VT. Additional voxelwise SUVR group analyses were 
performed.  
We observed no significant group differences in pseudo-reference VT or SUV, 
excepting whole-brain VT, which was higher in cLBP patients than controls. Target VT 
elevations in patients (p=0.028 and 0.051 in cLBP and ALS, respectively) were similarly 
detected by SUVRoccip and SUVRWB, and by refDVR and blDVR (less reliably by 
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SUVRcereb). In voxelwise analyses, SUVRoccip, but not SUVRcereb, identified regional group 
differences initially observed with SUVRWB, and in additional areas suspected to be 
affected in the pathology examined. All ratio metrics were highly cross-correlated, but 
generally were not associated with VT.  
While important caveats need to be considered when using relative metrics, ratio 
analyses appear to be similarly sensitive to detect pathology-related group differences in 
11C-PBR28 signal as classic kinetic modeling techniques. Occipital cortex may be a 
suitable pseudo-reference region, at least for the populations evaluated, pending further 
validation in larger cohorts.  
Keywords: Neuroinflammation, human, microglia, astrocytes, neuroimmunology. 
 
INTRODUCTION 
 A growing body of work indicates that neuroinflammation, and more specifically 
glial activation, plays an important role in the pathophysiology of many neurological 
disorders, ranging from schizophrenia to chronic pain (1). Arguably, the most commonly 
evaluated targets for in vivo visualization of glial activation is TSPO (2). TSPO is strongly 
upregulated in activated microglia and reactive astrocytes during brain and spinal 
neuroinflammatory states (3), and can be imaged with PET radiotracers like 11C-PBR28.  
Using 11C-PBR28 with classical kinetic modeling measures various groups have 
detected elevated PET signal in a variety of conditions with a known or suspected 
inflammatory component, including Alzheimer’s Disease (4,5), human immunodeficiency 
virus (6) and epilepsy (7), among others. Despite these promising results, interpretation 
of TSPO PET signal is often complicated by substantial interindividual variability. For 
instance, large variability is commonly observed when 11C-PBR28 binding is quantified by 
VT estimation with AIF (8), which is considered by many to be the gold standard for 
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quantification of TSPO binding. Such variability, which may be associated with multiple 
factors not necessarily linked to neuroinflammation, including genetically-explained 
differences in radioligand binding affinity (9), variability in vascular TSPO binding (10), or 
binding to plasma protein (11) needs to be accounted for in order to identify group effects 
that are truly reflective of neuroimmune activation. However, while the effect of genotype 
on TSPO PET signal is well documented (9,12,13), the extent to which variability in 
vascular or plasma binding affects TSPO PET data remains to be characterized. 
One way to account for such global variability is to scale 11C-PBR28 uptake 
(either estimated using kinetic modeling or through simplified methods such as SUV) by a 
normalizing factor. Of course, the use of relative outcome measures precludes the 
absolute quantification of protein expression, which is a strength of PET imaging. 
However, previous work showing ratio metrics can detect group differences with similar 
sensitivity to traditional kinetic modeling (4) suggests that these approaches may be 
beneficial under certain circumstances. Several studies have normalized 11C-PBR28 
uptake with average signal of the whole brain or whole gray matter (6,8,14-18). While this 
approach may improve the detection of focal effects by robustly reducing between-
subject variability, it also carries a penalty in that it reduces sensitivity to detect spatially 
extended effects. This becomes particularly problematic when the condition investigated 
is characterized by global, rather than regional, inflammation (e.g., neurological disorders 
demonstrating widespread neurodegeneration, exposure to lipopolysaccharide challenge, 
etc), and thus the reference region signal will contain signal from target regions. 
Therefore, the identification of a more focal reference region is desirable (4). Due to the 
lack of a true TSPO reference region devoid of specific binding (19), a suitable pseudo-
reference region, relatively unaffected by pathology, must be identified.  
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 In the present investigation, we evaluated analytical approaches employing 
different pseudo-reference regions for 11C-PBR28 PET imaging, and compared them with 
standard kinetic modeling techniques  
 
MATERIALS AND METHODS 
Study Design 
In this study, we reanalyzed two disease cohorts from previously reported 
datasets, cLBP (14) and ALS (17), along with corresponding healthy control subjects. We 
evaluated cerebellum, occipital cortex, and whole brain as putative pseudo-reference 
regions. The cerebellum was chosen to evaluate the generalizability to other disorders of 
the results by Lyoo et al. (4), who had shown this region to be a viable pseudo-reference 
for 11C-PBR28 studies in Alzheimer’s Disease. The occipital cortex was chosen because 
it is thought to be relatively spared from pathology in patients suffering from either chronic 
pain (20,21) or ALS (22,23). The whole brain has been used to normalize signal in the 
original cLBP and ALS publications, as well as in other studies (14,15,17,18). In order to 
compare the effect of the regional pseudo-reference approach to the original analyses, 
which used SUV normalized by whole brain (SUVRWB), the same preprocessing and 
group analyses from the original studies were replicated, preserving the existing across-
studies differences in design and image processing. 
Detailed information about the analytical strategies employed are presented 
below. In brief, initial characterization of candidate pseudo-reference regions was 
performed by testing for the absence of group differences in VT, estimated with AIF and 
traditional two-tissue compartmental modeling (2TCM), and SUV. Subsequently, the 
sensitivity to detect SUVR ROI group differences in “target regions” [i.e. regions showing 
the largest group differences in the original studies; bilateral thalamus (cLBP) and 
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bilateral precentral gyrus (ALS)] was compared to that using VT. Additional SUVR group 
analyses were performed in a whole brain voxelwise approach. The pseudo-reference 
region providing the greatest sensitivity to detect group differences in the preliminary 
SUVR analyses (i.e., occipital cortex, see Results) was then further assessed, by 
computing distribution volume ratio estimated with (blDVRoccip) or without AIF 
(refDVRoccip).  
All datasets were acquired at the Athinoula A. Martinos Center for Biomedical 
Imaging at Massachusetts General Hospital. All protocols were approved by the 
Institutional Review Board and Radioactive Drug Research Committee, and all subjects 
signed a written informed consent. 
 
Subjects 
Demographic information from the participants has previously been published 
(14,17). Briefly, the cLBP study consisted of 10 patients and 9 healthy controls, evaluated 
in a matched pairs design (with two patients matched to the same control). The ALS 
study consisted of 10 patients and 10 controls (8 of whom were scanned as part of the 
cLBP study) demographically matched but not individually paired with ALS patients 
(Supplemental Table 1).  
 
Image Acquisition 
Ninety-minute dynamic 11C-PBR28 scans were performed with an integrated 
PET/MRI scanner consisting of a dedicated brain avalanche photodiode-based PET 
scanner in the bore of a Siemens 3T Tim Trio MRI (24). A multi-echo MPRAGE volume 
was acquired prior to tracer injection (TR/TE1/TE2/TE3/TE4 = 2530/1.64/3.5/5.36/7.22 
ms, flip angle = 7°, voxel size = 1mm isotropic) for the purpose of anatomical localization, 
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spatial normalization of the imaging data, as well as generation of attenuation correction 
maps (25). For either cohort, mean injected dose and injected mass were not significantly 
different across groups (Supplemental Table 1).  
 
Arterial Plasma and Metabolite Analysis 
For the first 3 minutes post-injection, arterial blood samples were collected at 6-
10s intervals, followed by additional samples at 5, 10, 20, 30, 60, and 90 minutes for 
plasma and metabolite analysis. Parent fraction in plasma was determined as follows. 
Arterial blood was centrifuged immediately following collection to separate plasma. A 
600μL plasma aliquot was removed and added to 600μL acetonitrile to cause protein 
precipitation. After centrifugation, a 300μL aliquot of supernatant was removed and 
diluted into 4mL water. This sample was loaded on a HyperSep C18 solid extraction 
cartridge (500mg media) that had been prewashed with ethanol and equilibrated with 
aqueous trifluoroacetic acid (0.1%). The flow through was collected as elution volume 1 
and the column was eluted in 7 additional steps (4mL eluent) at the following acetonitrile 
percentages: 0, 10, 20, 30, 40, 70, 100, with the balance being 0.1% trifluoroacetic acid. 
The unmetabolized compound (assigned by control experiments) was collected in elution 
volumes 5 through 8. The ratio of summed radioactivity in elution volumes 5 though 8 
(parent compound) was taken relative to the total radioactivity eluted to determine the 
parent fraction for each time point. Five plasma outliers were excluded, as they fell 
outside the range of median ± 2.5*median absolute deviation (26). Another two subjects’ 
data were excluded due to technical complications that prevented completion of arterial 
sampling. 
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Data Analysis 
Static Image Generation. 60-90 minute SUV images were generated as 
described previously (14,17). MPRAGE-based attenuation correction was performed 
according to published methods (25). SUV maps were transformed to MNI space and 
smoothed with an 8mm (cLBP) or 6mm (ALS) full width at half maximum Gaussian kernel, 
as in the respective original analyses (14,17). Finally, SUV frames were normalized by 
average uptake in cerebellum (SUVRcereb) and occipital cortex (SUVRoccip) for comparison 
against previously reported SUVRWB.  
Dynamic Image Generation. Dynamic 11C-PBR28 scans were reconstructed 
using in-house software with the following time-frames: 8x10s; 3x20s; 2x30s; 1x60s; 
1x120s; 1x180s; 8x300s; 4x600s. Frame-by-frame motion correction was performed, and 
data were converted to SUV by dividing by injected radioactivity/lean body mass. To 
characterize dynamic activity in candidate pseudo-reference regions and whole brain, 
SUV time activity curves were extracted from images in subject-space. Dynamic data 
were unavailable for one control in the ALS cohort, and this subject was excluded from all 
dynamic analyses. 
Kinetic modeling. VT was estimated for all target and reference regions using 
2TCM with a fixed blood volume of 5% (19). For plasma processing, parent plasma 
fraction curves were fitted to a bi-exponential function. Plasma curves were fitted to a tri-
exponential function, and combined with interpolated parent fractions to yield a 
metabolite-corrected plasma curve (see Supplemental Fig. 1 for example fits for both 
parent fraction and plasma input function). Arterial plasma data were unavailable for one 
cLBP and one ALS patient (for technical difficulties during the scan, as mentioned 
above); therefore, these subjects were excluded from all blood-based analyses. As the 
occipital cortex emerged as the preferred candidate for pseudo-reference region (see 
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Results), we proceeded with kinetic modeling of ratio metrics using only this brain area. 
Occipital DVR was estimated in two ways with in-house Matlab code, both implementing 
Logan graphical analysis [reference-based (27) and blood-based (28)] with t*=15 minutes.  
First, we used the occipital time activity curve as an input function to obtain DVR 
(refDVRoccip). Then, we computed AIF-derived DVR (blDVRoccip) by dividing target VT by 
occipital cortex VT. We chose Logan-based methods as primary analytical approaches for 
ratio metrics, as in previous 11C-PBR28 studies (29,30), because they allow a direct 
comparison of VT estimations with AIF as well as blood-free pseudo-reference tissue 
inputs (a secondary aim in the present study). 
 
Statistical Analysis 
In order to evaluate the viability of putative pseudo-reference candidate regions, 
we first sought to demonstrate that PET signal in these regions was not different across 
groups, which would preclude their utility as pseudo-reference regions. To this end, we 
compared VT and SUV across groups for cerebellum, occipital cortex, and whole brain. 
For SUV analyses, we used the same nonparametric tests employed in the previous 
publications [Wilcoxon signed rank test for cLBP (14); Mann-Whitney U test for ALS (17)]. 
Subsequently, we used the same statistical tests to evaluate the ability of different ROI-
based analytical approaches (SUVR, refDVR) to detect group differences in target 
regions. Because outlier exclusion unbalanced the relative proportion of high- and mixed-
affinity binders in both cLBP and ALS groups, an unpaired one-way ANOVA with group 
and genotype as fixed factors, and a group*genotype interaction term was used to 
assess group differences in blDVR and VT. 
Group differences were interrogated with target region SUVR, and compared to 
differences obtained with VT. Receiver operating characteristic (ROC) curves were then 
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employed to further characterize the ability of each candidate pseudo-reference region to 
distinguish patients from controls based on mean target region SUVR, in comparison to 
target VT. Area under the ROC curve (AUROC) was used as an outcome measure 
(AUROC=1 represents perfectly accurate group classification, or 100% specificity and 
sensitivity, and AUROC=0.5 indicates discriminatory power equivalent to chance). Whole 
brain voxelwise SUVR analyses were also performed for comparison with the SUVRWB 
data previously reported (14,17). Briefly, these analyses were conducted using the 
randomise tool from the FSL suite, with threshold-free cluster enhancement (31), and a 
corrected threshold of p < 0.05. Relationships between VT, SUV, SUVR, and DVR were 
assessed with Pearson’s r. In the cLBP dataset, because 2 patients matched the same 
control, the SUVR ROI and voxelwise group comparisons were repeated in two separate 
matched-pairs analyses, using one of the two patients matched control, as described 
previously (14). Because results using both patients were similar, we present here group 
comparisons utilizing the “best match” (in terms of age). However, because one of these 
two cLBP matching patients lacked arterial plasma data, the VT and blDVR (and, for 
consistency, refDVR) analyses were performed only with the patient for whom these data 
were available. In the unpaired group and correlation analyses, all available data were 
used.  
 
RESULTS 
Descriptive statistics for all outcome measures are shown in Table 1. 
 
SUV and VT  in Candidate Pseudo-reference Regions 
There were no significant group differences in SUV for any of the pseudo-
reference regions (Fig. 1, left). No significant group differences in VT were observed for 
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occipital and cerebellar pseudo-reference regions, for either study; however, there was a 
significant group difference for whole brain VT in the cLBP study, with the patients 
exhibiting higher values than controls (p < 0.05; Fig. 1, right). SUV time activity curves 
from 0 – 90 minutes for each candidate pseudo-reference region are presented in Figure 
2. 
 
Target VT Group Differences 
Group comparisons between target VT yielded a statistically significant difference 
in thalamus for cLBP patients (p < 0.05), and trended towards significance in the 
precentral gyrus for ALS patients (p=0.051; Fig. 3). 
 
Target SUVR Group Differences 
Results from both cohorts indicated that the most significant group differences in 
target SUVR were obtained using occipital cortex and whole brain as normalizing regions, 
followed by cerebellum (Fig. 4). ROC curves confirmed that SUVRoccip and SUVRWB 
yielded better sensitivity to detect group differences than SUVRcereb (Fig. 5). SUVRoccip 
displayed the largest area under the ROC curve (AUROC; cLBP: SUVRoccip – 0.988, 
SUVRWB – 0.951, SUVRcereb – 0.840; ALS: SUVRoccip – 0.790, SUVRWB – 0.770, 
SUVRcereb – 0.680). For comparison, Figure 5 also shows the ROC curves obtained using 
target VT (AUROC: 0.792 and 0.771 for the cLBP and ALS studies, respectively). 
 
Voxelwise SUVR Group Differences 
For both cLBP and ALS cohorts, voxelwise SUVRoccip analysis revealed several 
cortical and subcortical regions exhibiting greater signal in patients than controls (Fig. 6). 
Several of these regions were consistent with those from the original SUVRWB analyses 
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[cLBP: thalamus, paracentral lobule, and precentral and postcentral gyri (14); ALS: 
supplementary motor area, corticospinal tract, paracentral lobule, and precentral gyrus 
(14)]. However, using SUVRoccip, several additional regions with significant group 
differences emerged [cLBP: posterior insula, striatum, anterior midcingulate and posterior 
cingulate cortices and others (Supplemental Table 2); ALS: dorsomedial, dorsolateral, 
ventrolateral, and ventromedial prefrontal cortices, anterior midcingulate cortex and 
others (Supplemental Table 3)]. Importantly, group differences were present in these 
same regions for the SUVRWB analysis if the significance threshold was lowered to a 
significantly less stringent value (Supplemental Fig. 2). There were no regions where 
SUVR was greater in controls than patients for any pseudo-reference region. There were 
no significant group differences from the SUVRcereb analysis.  
 
DVR Group Differences   
Because the occipital cortex emerged as the preferred pseudo-reference region, 
based on the results presented above, additional ratio metrics were computed using this 
brain area only. Group comparisons between target refDVRoccip and blDVRoccip yielded 
significant differences between patients and controls for both the CLBP and ALS studies, 
similar to the VT and SUVR ROI analyses (Fig. 7).  
 
Associations Across Metrics 
Overall, all ratio metrics were highly cross-correlated (Supplemental Table 4), but 
generally did not correlate well with VT. Target SUVRoccip was strongly correlated with 
both refDVRoccip and blDVRoccip for both cLBP and ALS groups (Supplemental Fig. 3), 
even with plasma outliers included (Supplemental Fig. 4). In the cLBP group, thalamus VT 
was significantly correlated with SUVRoccip (p < 0.05) and SUVRWB (p < 0.001), and 
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showed a trend-level correlation with blDVRoccip (p = 0.059). However, there were no 
other statistically significant correlations between target VT and SUVR, refDVRoccip, or 
blDVRoccip (p’s ≥ 0.21). Target regions were highly intercorrelated with all reference 
regions for both VT and SUV (p’s ≤ 1.3 x 10-4). Target and occipital cortex VT estimated 
with 2TCM were highly correlated with VT estimated with Logan graphical analysis 
(Supplemental Fig. 5).   
 
DISCUSSION     
Our study suggests that quantitation of 11C-PBR28 PET signal via pseudo-
reference approaches, with or without AIF, can detect group differences with similar 
sensitivity to analysis with traditional VT estimates, for the cLBP and ALS datasets 
presented here. In particular, the occipital cortex emerged as a preferred pseudo-
reference region, as it displayed no significant group differences, and relative metrics 
using occipital cortex as a pseudo-reference region yielded the highest sensitivity to 
detect group differences in both target ROI and whole-brain voxelwise analyses. 
Voxelwise differences in 11C-PBR28 SUVRoccip were present in the original SUVRWB 
analyses if the significance threshold was lowered to a much less stringent value (14,17). 
Thus, the use of a localized pseudo-reference region led to increased power to detect 
group differences. This suggests that spatially diffuse group differences in TSPO signal 
might contribute to the normalizing signal when using whole brain as a pseudo-reference 
region. Indeed, we found that whole brain VT was higher in patients compared to controls, 
at least for cLBP. This highlights the benefit of using a more focal pseudo-reference 
region devoid of signal from “target” regions, rather than the use of whole brain or whole 
gray matter signal, as has been done previously). While additional validation in larger 
studies is warranted, our observations suggest that occipital cortex may be a suitable 
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pseudo-reference region for studies involving 11C-PBR28 in these clinical populations, 
and perhaps in other patient groups in which the occipital cortex is thought to be relatively 
spared from pathology.  
Blood-free methods for quantifying TSPO tracer binding, such as those used in 
the current study, are extremely attractive for clinical applications. Quantification with 
kinetic modeling and AIF does not translate well to clinical settings, as it is invasive and 
requires an experienced practitioner (e.g., an anesthesiologist) to place an arterial 
catheter. Furthermore, quantifying TSPO tracer binding with VT (with or without 
normalization by plasma free fraction (fP) is associated with large variability that may be 
attributable to challenges in obtaining accurate blood measurements in addition to 
physiological variability (8,18).  
Of note, our criteria for assessing the suitability of analyses using ratio metrics for 
TSPO imaging included their ability to replicate group differences observed using VT, as 
well as their sensitivity to detect group differences in regions where neuroinflammatory is 
known or expected. Of course, for the latter criterion to be satisfied, the PET signal 
elevations should match known patterns of glial activation in the disorders under 
investigation, possibly based on post-mortem or other direct investigations.  In ALS, 
considerable evidence links glial activation to neuropathology (32), and post-mortem data 
have demonstrated a direct association between increased glial activation in the motor 
cortex and more rapid disease progression (33). These in vitro data are supported by 
numerous in vivo imaging studies (17,34-36). As such, ALS presents an excellent 
opportunity to perform validation studies using the approaches employed in this study. 
Regarding chronic pain, activation of microglia and/or astrocytes has been reported in the 
spinal cord in patients with HIV-associated neuropathy (37) and complex regional pain 
syndrome (38). While post-mortem data directly demonstrating the spatial pattern of pain-
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related immunoactivation in the brain is so far unavailable, several preclinical studies 
report its occurrence in numerous brain regions, including thalamus, somatosensory 
cortex, ventral striatum, and ventral tegmental area (39-41).   
Using occipital cortex normalization, we found that the elevated 11C-PBR28 
signal originally reported with SUVRWB (e.g., thalamus, somatosensory and motor 
cortices in cLBP patients; motor/premotor cortices in ALS patients) became more bilateral 
and pronounced with SUVRoccip. Importantly, many of these are regions that have 
exhibited glial activation in preclinical models of chronic back pain (39,41) and in post-
mortem and preclinical studies of ALS (32,33). Furthermore, in both disease cohorts we 
observed additional regions of significantly increased PET signal previously observed 
only well below threshold, and within structures affected by the respective pathologies. In 
cLBP patients, we observed elevated PET signal in the middle/anterior cingulate cortex 
(Fig. 5; Supplemental Table 1), in which glial activation has been suggested to underlie 
the affective component of pain in neuropathic pain models (42,43). Additionally, group 
effects were also detected in the ventral tegmental area and the ventral striatum, reward-
processing regions that exhibit microglial activation in animal neuropathic pain models 
(40,41). In ALS patients, voxelwise SUVRoccip analysis revealed additional clusters in 
several regions, including prefrontal regions and anterior cingulate cortex (Fig. 6; 
Supplemental Table 2), which is in line with recent post-mortem data demonstrating 
increased inflammatory markers in the frontal cortex of ALS patients (44).  
We also reported that analysis of both refDVR and blDVR yielded group 
differences comparable to the analysis with VT and SUVR, and these outcomes were 
strongly correlated with SUVR measures. However, correlations between target VT and 
relative measures were not as robust as those between relative metrics. Further studies 
are warranted to investigate the observed dissociation between VT and ratio metrics.  
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It is important to stress that due to the large heterogeneity of clinical populations 
and TSPO tracer kinetics, the results presented here do not necessarily translate to other 
disorders with a neuroinflammatory component or other TSPO tracers. A cerebellar 
pseudo-reference region achieved successful group separation in Alzheimer’s Disease 
patients (4), but SUVRcereb did not detect similar group differences as with VT in the 
current study, or in a recent study of temporal lobe epilepsy (7). In the current sample, 
this is likely due to higher variability in SUVRcereb compared to SUVRoccip. These 
discrepant results emphasize the need for separate assessment of each clinical 
population and tracer of interest. 
Several caveats should be considered when interpreting the results of our study. 
Firstly, we did not measure fP. However, many previously published studies reported VT 
values without correction for fP (13,29), some electing not to incorporate it despite having 
collected it because of the excessive variability introduced by this measurement (15,30). 
Thus, it is currently unclear whether measurement of fP is beneficial for 11C-PBR28 
quantification. Secondly, studies using relative metrics need to be interpreted cautiously, 
and require careful validation in large cohorts to ensure the appropriateness of the region 
selected for pseudo-reference. For a region to be a suitable pseudo-reference, it should 
not display significant group differences. Although there were no group differences in 
uptake in our pseudo-reference regions (except for whole brain VT in the cLBP study), 
this does not exclude the possibility that small, non-significant differences could bias the 
outcome measure. There was also a high degree of correlation between target and 
reference SUV and VT, which means a large part of the signal is removed from the target 
region, some of which may be biologically relevant. Finally, recent evidence suggests that 
vascular TSPO binding may affect quantification (10). Given the known heterogeneity of 
cerebral vascularization (45), it is possible that regional differences in vascular physiology 
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(e.g. density) could affect binding differentially, which could lead to bias with pseudo-
reference strategies. However, the contributions of differential vascularization to tracer 
quantification are not well characterized. 
 
CONCLUSION 
 In the current study, we present evidence indicating that approaches employing 
ratio metrics appear to be similarly sensitive to detect pathology-related group differences 
in 11C-PBR28 signal as classic kinetic modeling techniques, at least for the populations 
evaluated here. However, the reasons behind the largely non-significant associations 
between relative metrics and VT needs to be further elucidated. The occipital cortex 
emerged as the preferred pseudo-reference region, as its signal was not significantly 
different across groups, and all ratio metrics based on the signal from this region 
detected group differences similar to those detected by VT, In addition, in the voxelwise 
analysis, SUVRoccip identified regions of increased glial activation that included those 
detected from the initial analyses, as well as several additional regions that were relevant 
to the respective pathologies and have been shown to exhibit glial activation in preclinical 
models and/or post-mortem data. It is important to stress that caveats should be kept in 
mind when using relative measures, and that the choice of an appropriate pseudo-
reference region needs to be pathology-dependent and may not be possible in some 
cases (e.g., where neuroinflammation is expected to span the entire brain parenchyma). 
In general, these techniques will require additional validation before widespread use.  
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FIGURE 1. Group comparison of SUV (left) and VT (right) from candidate pseudo-
reference regions evaluated in this work. Boxes represent the 25%- 75% interquartile 
range; horizontal line represents the median. Diamonds represent subjects with the high-
affinity TSPO genotype (Ala/Ala in the Ala147Thr TSPO polymorphism), squares 
represent subjects with mixed-affinity genotype (Ala/Thr).  
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FIGURE 2. Group comparison of 0-90 minute time activity curves for candidate pseudo-
reference regions. Each data point represents the average within-group SUV for that time 
point ± SD. In the cLBP plots (left) both patients matching the same control subject are 
included.  
  
by King's College London on August 31, 2017. For personal use only. jnm.snmjournals.org Downloaded from 
 26
 
FIGURE 3. Group comparison of target VT estimates for cLBP (top) and ALS (bottom) 
groups.  
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FIGURE 4. Group differences in target SUVR for each pseudo-reference region. 
Horizontal bars represent group median. In the cLBP plots (top) both patients matching 
the same control subject are included as data points, but the median value reflects only 
the best matching patient included.  
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FIGURE 5. Receiver operating characteristic (ROC) curves of target SUVR (dashed 
lines) and VT (solid line) for each pseudo-reference region. Line of identity (chance, no 
discriminatory power) is shown in black. 
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FIGURE 6. Regions of elevated 11C-PBR28 SUVR in patients compared to controls. 
Results from SUVRWB analyses (analyses from the original studies) are shown in green 
colorscale, SUVRoccip results are shown in red-yellow colorscale. Top: cLBP > controls 
Bottom: ALS > controls. No regions was significant in either cLBP < controls or ALS < 
controls contrasts. PCC – posterior cingulate cortex; aMCC – anterior midcingulate 
cortex; SCA – subcallosal area; Thal – thalamus; SMA – supplementary motor area; 
dmPFC – dorsomedial prefrontal cortex; vmPFC – ventromedial prefrontal cortex.  
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FIGURE 7. Group comparison of refDVRoccip and blDVRoccip. Horizontal bars represent 
group median.  
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Measure cLBP CON (cLBP) ALS CON (ALS) 
SUV      
Target 0.698 ± 0.25 
(35.8%) 
0.525 ± 0.15 
(28.6%) 
0.495 ± 0.11 
(22.2%) 
0.488 ± 0.12 
(24.6%) 
Whole brain 0.470 ± 0.16 
(34.0%) 
0.412 ± 0.09 
(21.8%) 
0.416 ± 0.10 
(24.0%) 
0.441 ± 0.10 
(22.7%) 
Occipital  0.542 ± 0.21 
(38.7%) 
0.482 ± 0.11 
(22.8%) 
0.432 ± 0.13 
(30.1%) 
0.470 ± 0.11 
(23.4%) 
Cerebellum 0.556 ± 0.24 
(43.2%) 
0.497 ± 0.10 
(20.1%) 
0.460 ± 0.12 
(26.1%) 
0.480 ± 0.10 
(20.8%) 
VT     
Target 2.81 ± 0.84 
(29.9%) 
1.95 ± 0.71 
(36.4%) 
2.53 ± 0.75 
(29.6%) 
1.72 ± 0.60 
(34.9%) 
Whole brain 2.17 ± 0.59 
(27.2%) 
1.64 ± 0.58 
(35.4%) 
2.24 ± 0.73 
(32.6%) 
1.65 ± 0.59 
(35.8%) 
Occipital  2.27 ± 0.74 
(32.6%) 
1.82 ± 0.69 
(37.9%) 
2.33 ± 0.80 
(34.3%) 
1.82 ± 0.68 
(37.4%) 
Cerebellum 2.49 ± 0.85 
(34.1%) 
1.84 ± 0.71 
(38.6%) 
2.32 ± 0.91 
(39.2%) 
1.84 ± 0.71 
(38.6%) 
SUVR     
SUVRWB 1.27 ± 0.06 
(4.72%) 
1.12 ± 0.11 
(9.82%) 
1.14 ± 0.08 
(7.02%) 
1.06 ± 0.07 
(6.60%) 
SUVRoccip 1.23 ± 0.07 
(5.69%) 
1.03 ± 0.10 
(9.71%) 
1.12 ± 0.13 
(11.6%) 
1.00 ± 0.09 
(9.00%) 
SUVRcereb 1.22 ± 0.20 
(16.4%) 
1.00 ± 0.14 
(14.0%) 
1.04 ± 0.13 
(12.5%) 
0.984 ± 0.17 
(17.3%) 
refDVRoccip 1.16 ± 0.08 
(6.70%) 
1.03 ± 0.16 
(15.5%) 
1.11 ± 0.12 
(10.8%) 
0.980 ± 0.08 
(8.16%) 
blDVRoccip 1.25 ± 0.11 
(8.80%) 
1.08 ± 0.10 
(9.26%) 
1.11 ± 0.13 
(11.7%) 
0.951 ± 0.07 
(7.36%) 
TABLE 1. Descriptive statistics for all outcome measures. Values are mean ± S.D., 
with %COV shown in parentheses below. “Target” refers to regions showing the largest 
group differences in the original studies; bilateral thalamus (cLBP) and bilateral precentral 
gyrus (ALS). Values for blood-based measures (VT and blDVR) exclude plasma outlier 
subjects. 
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SUPPLEMENTAL FIGURE 1. Examples of model fitting for parent fraction and plasma 
activity for two representative subjects. Actual datapoints are shown as blue stars, 
exponential model fit of the data is shown as a red line. Left: parent fraction fits for a 
control subject (top) and patient (bottom). Right: plasma activity fits for a control subject 
(top) and patient (bottom). The bottom subpanel is on a logarithmic scale to show fitting 
of the peak. 
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SUPPLEMENTAL FIGURE 2. Regions of elevated 11C-PBR28 SUVRWB in patients 
compared to controls, visualized at an extremely lenient statistical threshold (p<0.25). 
These results show group differences highly overlapping with those observed at strict 
threshold with the SUVRoccip analyses (Fig. 5). Top: cLBP > controls. Bottom: ALS > 
controls. No region was significant in either the cLBP < controls or ALS < controls 
contrasts. 
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SUPPLEMENTAL FIGURE 3. Relationship between target SUVRoccip, refDVRoccip, and 
blDVRoccip. Line of identity is shown in black.  
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SUPPLEMENTAL FIGURE 4. Relationship between target SUVRoccip, refDVRoccip, and 
blDVRoccip, plasma outliers included and identified. Line of identity is shown in black.  
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SUPPLEMENTAL FIGURE 5. Relationship between Logan and 2TCM estimations of 
target and occipital cortex VT. Line of identity is shown as a dotted diagonal line. Plasma 
outliers are not included. 
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SUPPLEMENTAL TABLE 1. Subject demographics 
 cLBP CON (cLBP) ALS CON (ALS) 
N 10 9 10 10 
Sex  5M/5F 5M/4F 6M/4F 6M/4F 
TSPO 
Genotype 
7 Ala/Ala;  
3 Ala/Thr 
7 Ala/Ala;  
2 Ala/Thr 
6 Ala/Ala;  
4 Ala/Thr 
6 Ala/Ala;  
4 Ala/Thr 
Age (years) 48.9 (12) 49.6 (12) 53.2 (11) 51.1 (11) 
Injected Dose 
(MBq) 
409.5 (27.9) 407.4 (15.4) 429.7 (33.8) 424.5 (42) 
Injected mass 
(nmol/kg) 
0.06 (0.02) 0.10 (0.07) 0.06 (0.02) 0.11 (0.07) 
Values shown are mean ± standard deviation. 
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SUPPLEMENTAL TABLE 2. Regions of voxelwise increases in [11C]PBR28 SUVRoccip in 
cLBP patients compared to controls.  
  MNI coordinates 
(mm) 
 
Region P-
value 
(corr) 
X Y Z Cluster size (# 
voxels) 
L Thalamus 0.006 -4 -18 0 1871 
R Thalamus 0.016 2 -18 0 
L Putamen 0.021 -22 6 2 
L Caudate 0.029 -14 14 6 
L Subcallosal area 0.033 -4 14 -16 
L Ventral striatum 0.035 -6 8 -6 
 
L Paracentral lobule 0.008 -8 -22 50 7236 
L Postcentral gyrus 0.008 -18 -38 64 
L Posterior midcingulate cortex 0.012 -6 -20 44 
L Precentral gyrus 0.016 -26 -12 56 
R Paracentral lobule 0.016 6 -32 58 
L/R Posterior cingulate cortex 0.018 0 -40 30 
R Precuneus 0.018 6 -58 50 
L Precuneus 0.020 -4 -60 38 
R Postcentral gyrus 0.020 24 -30 66 
R Precentral gyrus 0.021 20 -28 64 
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R Supramarginal gyrus 0.021 36 -50 38 
L Internal capsule 0.021 -16 12 2 
L Pre-supplementary motor 
area 
0.027 -8 2 48 
R Angular gyrus 0.029 30 -70 28 
Ventral tegmental area 0.033 0 -18 -8 
R Pre-supplementary motor 
area 
0.035 6 12 48 
L Anterior midcingulate cortex 0.035 -4 14 28 
Corpus callosum 0.035 -4 22 14 
L Supramarginal gyrus 0.049 -36 -42 40 
 
R Posterior Insula 0.018 36 -20 6 747 
S2 0.027 36 -28 18 
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SUPPLEMENTAL TABLE 3. Regions of voxelwise increases in [11C]PBR28 SUVRoccip in 
ALS patients compared to controls. 
  MNI coordinates 
(mm) 
 
Region P-
value 
(corr) 
X Y Z Cluster size (# 
voxels) 
L Precentral gyrus 0.000 -12 -20 62 21809 
L Superior frontal gyrus 0.002 -16 -6 58 
L Paracentral lobule 0.003 -2 -12 52 
L Postcentral gyrus 0.003 -26 -30 52 
L Supplementary motor area 0.003 -4 2 54 
R Precentral gyrus 0.004 24 -14 60 
R Paracentral lobule 0.004 4 -20 64 
R Supplementary motor area 0.004 10 2 60 
R Superior frontal gyrus 0.004 22 8 46 
L Corticospinal tract 0.004 -24 -24 42 
L Middle frontal gyrus 0.007 -26 14 46 
L Ventrolateral prefrontal cortex 0.007 -24 56 -2 
L Orbital gyrus 0.008 -30 26 -20 
L Dorsolateral prefrontal cortex 0.008 -34 40 26 
L Anterior midcingulate 
cortex/corpus callosum 
0.008 -6 24 18 
L Frontoinsular cortex 0.010 -34 24 0 
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R Anterior midcingulate cortex 0.013 6 14 32 
L Ventromedial prefrontal 
cortex 
0.014 -4 42 -12 
Dorsomedial prefrontal cortex 0.016 0 60 18 
R Pregenual anterior cingulate 
cortex 
0.019 12 44 -2 
 
R Orbital gyrus 0.047 14 26 -22 28 
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SUPPLEMENTAL TABLE 4. Interregional correlations between target and reference 
SUV and VT. 
Correlation between target and reference region SUV and VT 
Target and reference SUV 
Target region Reference region Control Patient 
r-value p-value r-value p-value 
Thalamus  
(CLBP dataset) 
Occipital cortex 0.956 1.6 x 10-5 0.988 < 1 x 10-6
Whole brain 0.922 1.4 x 10-4 0.961 1 x 10 -5
Cerebellum 0.881 7.5 x 10-4 0.948 3 x 10-5 
Precentral gyrus 
(ALS dataset) 
Occipital cortex 0.941 4.8 x 10-4 0.931 9.3 x 10-5 
Whole brain 0.962 9.0 x 10-6 0.950 2.6 x 10-5 
Cerebellum 0.829 3.0 x 10-3 0.873 9.7 x 10-4 
Target and reference VT 
Target region Reference region Control Patient 
r-value p-value r-value p-value 
Thalamus  
(CLBP dataset) 
Occipital cortex 0.947 4.1 x 10-3 0.956 2.0 x 10-4 
Whole brain 0.992 1.1 x 10-4 0.962 1.4 x 10-4 
Cerebellum 0.949 3.8 x 10-3 0.904 2.0 x 10-3 
Precentral gyrus 
(ALS dataset) 
Occipital cortex 0.974 1.0 x 10-3 0.949 3.2 x 10-4 
Whole brain 0.996 2.6 x 10-5 0.952 2.7 x 10-4 
Cerebellum 0.925 8.2 x 10-3 0.975 3.6 x 10-5 
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